1. Home
  2. BBCP vs GLSI Comparison

BBCP vs GLSI Comparison

Compare BBCP & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concrete Pumping Holdings Inc.

BBCP

Concrete Pumping Holdings Inc.

HOLD

Current Price

$7.15

Market Cap

356.0M

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$25.34

Market Cap

372.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBCP
GLSI
Founded
1983
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
356.0M
372.0M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
BBCP
GLSI
Price
$7.15
$25.34
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$8.25
$50.00
AVG Volume (30 Days)
101.4K
150.2K
Earning Date
03-10-2026
04-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$392,867,000.00
N/A
Revenue This Year
$3.49
N/A
Revenue Next Year
$0.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.04
$7.78
52 Week High
$7.80
$34.10

Technical Indicators

Market Signals
Indicator
BBCP
GLSI
Relative Strength Index (RSI) 58.90 47.90
Support Level $6.64 $21.43
Resistance Level $7.28 $29.91
Average True Range (ATR) 0.32 2.25
MACD -0.00 -0.19
Stochastic Oscillator 76.73 35.48

Price Performance

Historical Comparison
BBCP
GLSI

About BBCP Concrete Pumping Holdings Inc.

Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: